We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Monday
May 09
11:40 - 12:40
Room D1
Highlights of Proffered Papers - Latest Clinical Trials
Anna Kirby, United Kingdom;
Ben Slotman, The Netherlands
Proffered Papers
Interdisciplinary
12:00 - 12:10
Results of ARTIX phase III study: adaptive radiotherapy versus standard IMRT in head and neck cancer
Renaud de Crevoisier, France
OC-0831

Abstract

Results of ARTIX phase III study: adaptive radiotherapy versus standard IMRT in head and neck cancer
Authors:

Joël Castelli1, Karen Benezery2, Ali Hasbini3, Bernard Gery4, Antoine Berger5, Xavier Liem6, Sebastien Guihard7, Sophie Chapet8, Sebastien Thureau9, Pierre Auberdiac10, Pascal Pommier11, Juliette Thariat12, Boris Campillo13, Renaud de Crevoisier14

1Centre Eugene MArquis, Radiotherapy, Rennes, France; 2Centre Antoine Lacassagne, Radiotherapy, Nice, France; 3Clinique Pasteur Lanroze , Radiotherapy, Brest, France; 4Centre François Baclesse, Radiotherapy, Caen, France; 5CHU poitiers, Radiotherapy, Poitiers, France; 6Centre Oscar Lambret, Radiotherapy, Lille, France; 7Centre Paul Strauss, Radiotherapy, Strasbourg, France; 8CHU Tours, Radiotherapy, Tours, France; 9CLCC Rouen - Becquerel, Radiotherapy, Rouen, France; 10Clinique Médico- Chirurgical et Obstétrical Claude Bernard, Radiotherapy, Albi, France; 11Centre Léon Bérard , Radiotherapy, Lyon, France; 12Centre Baclesse, Radiotherapy, Caen, France; 13Centre Eugene Marquis, Clinical investigations, Rennes, France; 14Centre Eugene Marquis, Radiotherapy, Rennes, France

Show Affiliations
Purpose or Objective

Patients with stage III or IV with LAOC treated with chemoradiotherapy were randomly assigned to standard radiotherapy or systematic weekly replanning (ART). Primary endpoint was salivary flow measured at 12 months using parafilm stimulation. Secondary outcomes were overall survival, local control, scintigraphic assessment of salivary function and patient reported outcomes (PROM) (Eisbruch Xerostomia-specific questionnaire, MDASI-HN).

The ARTIX trial is a randomized multicentric study comparing a systematic weekly replanning (ART) with a standard IMRT for patients with a locally advanced oropharyngeal cancer (LAOC), with the aim of improving salivary function.

Material and Methods

Patients with stage III or IV with LAOC treated with chemoradiotherapy were randomly assigned to standard radiotherapy or systematic weekly replanning (ART). Primary endpoint was salivary flow measured at 12 months using parafilm stimulation. Secondary outcomes were overall survival, local control, scintigraphic assessment of salivary function and patient reported outcomes (PROM) (Eisbruch Xerostomia-specific questionnaire, MDASI-HN).

Results

A total of 132 patients were assigned to the experimental arm (n=67) or standard arm (n=65). The salivation flow measured using parafilm stimulation at 12 months was 630 mg/min in the experimental arm and 584 mg/min in the standard arm (p=0.6) (Figure 1). A significant difference was found regarding excretory function of the parotid gland with scintigraphy, with a mean value of 48 % in the experimental arm compared to 41% in the standard arm (p=0.015).  No significant difference was found regarding overall survival, local control and patient reported outcomes (Figure 2 : Evolution of Eisbruch score by arms)


Figure 1 : Time evolution of the salivation flow by arms

Evolution of the salivation flow measured by parafilm stimulation at the inclusion, 6, 12, 18 and 24 months after treatment

StnA = Standard Arm
RplA = Experimental arm (weekly replanning)

Figure 2 :Evolution of Eisbruch score by arms

Conclusion

No significant benefit of ART was found regarding salivary flow and PROM. However, ART allows to improve the excretory function of the parotid gland compared to a standard IMRT, without decreasing local control and overall survival.